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Abstract
Background: Recent studies have identified MUC4 mucin as a ligand for activation of ErbB2, a
receptor tyrosine kinase that modulates epithelial cell proliferation following epithelial damage in
airways of asthmatics. In this study, we investigated the potential role of IL-4, one of the Th2
inflammatory cytokines persistent in asthmatic airways, in regulating MUC4 expression using a cell
line NCI-H650.
Methods: Real time PCR analysis was performed to determine concentration and time dependent
effects of IL-4 upon MUC4 expression. Nuclear run on experiments were carried out to explore
potential transcriptional modulation. Western blotting experiments using a monoclonal antibody
specific to ASGP-2 domain of MUC4 were performed to analyze MUC4 glycoprotein levels in
plasma membrane fractions. To analyze potential signal transduction cascades, IL-4 treated
confluent cultures were co-incubated, separately with a pan-JAK inhibitor, a JAK-3 selective
inhibitor or a MEK-1, 2 (MAPK) inhibitor at various concentrations before MUC4  transcript
analysis. Corresponding transcription factor activation was tested by western blotting using a
monoclonal p-STAT-6 antibody.
Results:  MUC4  levels increased in a concentration and time specific fashion reaching peak
expression at 2.5 ng/ml and 8 h. Nuclear run on experiments revealed transcriptional enhancement.
Corresponding increases in MUC4 glycoprotein levels were observed in plasma membrane
fractions. Pan-JAK inhibitor revealed marked reduction in IL-4 stimulated MUC4 levels and JAK3
selective inhibitor down-regulated MUC4 mRNA expression in a concentration-dependent fashion.
In accordance with the above observations, STAT-6 activation was detected within 5 minutes of
IL-4 stimulus. No effect in MUC4 levels was observed on using a MAPK inhibitor.
Conclusion: These observations signify a potential role for IL-4 in MUC4 up-regulation in airway
epithelia.
Background
Allergic asthma is an IgE-mediated condition character-
ized by airway hyper-responsiveness (AHR), chronic air-
way inflammation and epithelial cell damage [1-3]. These
changes in the airways are associated with increased influx
of activated CD4+ T-helper (Th) lymphocytes, which in
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turn, recruit eosinophils via the production of inflamma-
tory mediators, including cytokines (IL-4 and IL-5) and
chemokines (eotaxin) [4-7]. The eosinophils upon activa-
tion and recruitment cause epithelial cell damage by
release of cytotoxic proteins [8-10]. Following tissue dam-
age, the process of epithelial cell proliferation and restitu-
tion is broadly attributed to a subclass of receptor tyrosine
kinases (RTK) called the ErbB's [11,12]. ErbB family of
receptors is composed of four members, namely ErbB1,
ErbB2, ErbB3 and ErbB4. Phosphorylation of ErbB recep-
tors by ligand binding induces heterodimerization and
activation of specific signaling cascades. The ligands for
these receptors are epidermal growth factor (EGF) con-
served peptide growth factors [13]. In this context, MUC4,
an airway mucin with EGF-like domains in its transmem-
brane subunit, has been identified as a possible ligand for
ErbB2 receptor [14].
MUC4 is a large molecular weight membrane bound O-
glycoprotein expressed in the ciliated and goblet cells of
the trachea and bronchus [15]. Beyond the respiratory
tract, MUC4 is present in the epithelial tissues of stomach,
breast, endocervix, cornea and colon [16,17]. Structurally,
MUC4 is a heterodimeric complex consisting of a large
850 kD membrane bound MUC4α subunit and a smaller
80 kD trans-membrane MUC4β subunit [18]. The larger
MUC4α subunit is believed to exhibit anti-adhesive prop-
erties and to protect the apical surfaces of epithelial cells
[19]. In contrast, MUC4β subunit possesses two EGF-like
domains that bind to ErbB2 receptors and modulates epi-
thelial cell proliferation or differentiation [20]. However,
some reports indicate the presence of three EGF domains
in the trans-membrane subunit [21].
Clinical and experimental evidence suggests a central role
for IL-4 in the development and maintenance of AHR in
allergic asthmatics [22]. IL-4 is also reported to play a sig-
nificant role in secretory cell metaplasia increasing the
area of mucus secreting cells in airways. For instance, sep-
arate studies with transgenic mice distinctively expressing
IL-4 in the lungs showed goblet cell metaplasia [23], aller-
gen challenged STAT-6-deficient mice (IL-4R signaling-
impaired mouse airways) showed a marked reduction in
the same phenomenon [24]. Furthermore, IL-4 was
reported to enhance mucus production in cultured airway
epithelial cell line NCI-H292 and to up-regulate MUC
genes in mouse airways [25].
Earlier, studies involving MUC genes were performed to
explain a mucus hypersecretory phenotype in chronic air-
way inflammatory states. Consequently, those studies
explored the effects of cytokines and proteolytic enzymes
upon a variety of secretory mucin genes including MUC2,
MUC5AC, MUC5B and MUC8. Findings from these stud-
ies revealed a direct effect of inflammatory mediators
upon MUC gene regulation; nevertheless, ambiguity per-
sists, as to whether the regulatory pattern is exclusive to a
few or uniform across all known airway mucin genes. For
example, IL-4 decreases MUC5AC and increases MUC8
levels in cultured human nasal epithelial cells [26]; IL-9
increases  MUC2  and  MUC5AC  expression and has no
effect on MUC8 and MUC5B genes in bronchial epithelial
cells [27]; IL-13 was reported to increase MUC2  and
decrease MUC5AC expression in-vitro [28]. Further, the
effects of these inflammatory mediators on membrane-
bound mucins are not yet defined.
In a previous study, we demonstrated the effects of secret-
agogues, such as 8-bromocyclic AMP and neutrophil
elastase, on mucin secretions using a lung cancer cell line,
NCI-H650 [29]. Utilizing the same cell line in the present
study, we investigated the effects of IL-4 upon MUC4 gene
and glycoprotein expression. Regulation was established
to be at the transcriptional level. Using a variety of signal-
ing inhibitors we investigated the activation of janus
kinase (JAK) and mitogen-activated protein kinase
(MAPK) pathways. We further emphasized the phosphor-
ylation of the related transcription factor, STAT-6.
Methods
Cell culture
The human bronchoalveolar carcinoma cell line NCI-
H650 (ATCC, Manassas, VA) was cultured in serum free
ACL-4 media supplemented with 2 mM glutamine, 100
U/ml penicillin, 100 µg/ml streptomycin and 0.02 mg/ml
insulin. Cells were grown at 37°C in CO2 fully humidified
air and were sub-cultured twice weekly. The cell viability
was periodically determined by trypan blue exclusion
method.
Cell stimulation
The confluent cultures, in triplicate, were stimulated with
varying concentrations of human recombinant IL-4
(Sigma-Aldrich, Saint Louis, MO). Control groups were
treated with media alone. For MUC4 glycoprotein detec-
tion, cultures were treated with 2.5 ng/ml of IL-4 for 8 h,
washed and re-incubated in fresh medium devoid of IL-4
for an additional 16 h.
Inhibitor studies were carried out by pre-treating cultures
separately with 1,4-diamino-2,3-dicyano-1,4-bis(2-ami-
nophenylthio) butadiene (U0126), 2-(1,1-dimethyle-
thyl)-9-fluoro-3,6-dihydro-7H-benz [h]-imidazo [4,5-
f]isoquinolin-7-one (DBI) and 4-(4'-hydroxyphenyl)
amino-6, 7-dimethoxyquinazoline (WHI-P131) in
DMSO at varying concentrations (25–100 µM) for 30 min
before exposure to IL-4.Respiratory Research 2006, 7:39 http://respiratory-research.com/content/7/1/39
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Immunohistochemistry
The presence of IL-4 receptor α chain (part of IL-4R) on
the cell surface was established by using a rabbit polyclo-
nal anti-human IL-4Rα antibody (Santa Cruz Biotechnol-
ogy Inc, Santa Cruz, CA). The harvested cells were initially
washed with phosphate buffered saline (PBS) solution,
fixed in 4% paraformaldehyde for 5 min and permeabi-
lized in 0.1% Triton X-100. Blocking was performed with
4% BSA for 45 min before incubating with primary anti-
human IL-4R α Ab at 1:100 dilutions for 1 h. Secondary
incubations were performed with Alexa Fluor® (568 nm)
labeled mouse anti-rabbit Ab (Molecular Probes, Eugene,
OR) at 1:250 for 10 min. The cells were counterstained
with DAPI (Molecular Probes; 0.2 µg/ml in PBS) for 2 min
before visualizing on a Zeiss Axioplan 2 microscope. Dilu-
ent lacking primary Ab and non-immune rabbit IgG were
used as controls.
RNA extraction and reverse transcription
Total RNA was extracted by RNeasy Mini kit (Qiagen,
Valencia, CA) following the manufacture's protocol. The
DNase digestion of the RNA samples was performed on
RNeasy columns using the RNAse-free DNase set supplied
by the same manufacturer. The integrity of the eluted RNA
was confirmed by electrophoresing 5 µl of total RNA on
1.2% agarose/formaldehyde gels. The isolated RNA was
reverse transcribed using random hexamers and Super-
script II First Strand Synthesis kit (Invitrogen, Carlsbad,
CA) following the manufacturer's protocol.
Real-time PCR analysis
Real-time PCR amplifications were performed in the pres-
ence of flurogenic Taqman 6 Fam-Tamra probes on ABI-
Prism 7000 instrument (PE- Applied Biosystems, Foster
city, CA). Primers and Taqman probes for MUC4 were
sourced from published reports [30] while the endog-
enous human 18s rRNA standards were commercially
obtained from Applied Biosystems (Foster City, CA)
(Table 1). The optimal concentrations for MUC4 amplifi-
cation were determined to be 900 nM of forward, 300 nM
of reverse and final probe concentration of 100 nM per
reaction. Negative controls were performed omitting the
RT step before PCR amplifications. The relative abun-
dance of MUC4 was determined by ∆∆Ct method.
Nuclear run-on transcription assay
The modified assay involving PCR was adopted from ear-
lier published literature by Rolfe, et al. [31,32]. Nuclei
were extracted from control and IL-4 treated cells after 4
and 8 h using the Nuclei Ez Prep isolation kit (Sigma-
Aldrich, Saint Louis, MO). An additional, lyse/wash was
included in the protocol to improve the yields of nuclei.
Isolated nuclei were layered onto a sucrose cushion (2.1
M sucrose, 5 mM MgAc2, 1 mM EDTA, 10 mM Tris-HCl,
pH 8, 1 mM EGTA, 1 mM spermidine, 1 mM dithiothrei-
tol and 0.1 mM phenylmethylsulphonyl fluoride) by cen-
trifugation for 40 min at 16000 × g. Nuclei from treated
and control cells were split into two aliquots. One aliquot
(+NTP) was incubated for 45 min at 37°C in a solution
containing 20 % glycerol, 30 mM Tris-HCl, pH 8, 150 mM
KCl, 2.5 mM MgCl2, 1 mM dithiothreitol and 50 U of
RNAse OUT® (InVitrogen, Carlsbad, CA) and ATP, CTP,
GTP and UTP at 0.5 mM concentration each. The other
aliquot (-NTP) was incubated in the same solution with-
out nucleotides. After incubations, RNA was extracted,
reverse transcribed and analyzed by real-time PCR as
described above.
Plasma membrane protein extraction
Confluent cultures in triplicate were treated with 2.5 ng/
ml of IL-4 or control vehicle alone. The cells were initially
washed with ice cold PBS solution and recovered by cen-
trifugation at 600 × g for 5 min. Plasma membrane pro-
teins were isolated and purified by Plasma Membrane
Protein Extraction Kit (BioVision, Mountain View, CA),
following the manufacturers protocol. Protein content of
the purified samples was quantified by BCA assay kit
(Pierce biotech, Rockford, IL) using BSA as a standard.
Western blotting
Equal amounts of protein (50 µg) were resolved sepa-
rately on 4–20% SDS polyacrylamide gradient gels and
transferred to nitrocellulose membranes. The membranes
were then blocked by 5% dry milk in Tris-buffered saline
(20 mM Tris-HCl, pH 7.2, 150 mM NaCl) for 2 h at room
temperature and then incubated with 1:200 diluted
human MUC4-specific 1G8 monoclonal antibody
(Zymed labs, San Franciso, CA) for 1 h. Secondary anti-
body incubations were performed with 1:3000 dilution of
Table 1: Sequence of primers and probes used for Real-time PCR analysis.
Gene Sequence Size GenBank No
MUC4 Sense: 5'-GCCCAAGCTACAGTGTGACTCA-3'
Antisense: 5'-ATGGTGCCGTTGTAATTTGTTGT-3'
Probe: 5'-CGGCCACATCCCCATCTTCTTCAC-3'
102 bp AF058803
18S rRNA Eukaryotic 18S rRNA Endogenous Controls, Applied Biosystems (Foster City, CA) 186 bp X03205Respiratory Research 2006, 7:39 http://respiratory-research.com/content/7/1/39
Page 4 of 12
(page number not for citation purposes)
horseradish peroxidase-conjugated goat anti-mouse IgG
antibody. After three successive washes in TTBS (0.5%
Tween-20 in Tris-buffered saline), the membranes were
treated with HighSignal West Pico chemiluminescent sub-
strate (Pierce biotech, Rockford, IL) and exposed to
BioMax films (Eastman Kodak Co, Rochester, NY) for 1
min. Coomassie blue staining of gels was performed to
check for variations in sample loading.
For signal transduction experiments, confluent cultures
treated with IL-4 for 0, 5, 10, 15 and 20 min were lysed by
sonication on ice in lysis buffer (50 mM Tris-HCl, 150
mM NaCl, 1 mM EDTA, 1 mM PMSF, 1% Triton X-100,
0.1% SDS, 1% sodium deoxycholate, 5 µg/ml Aprotinin,
5 µg/ml Leupeptin). Equal amounts of cell lysates (50 µg)
were resolved on gels, transferred to membranes and
blocked as stated above. Blotting experiments were per-
formed by incubating the membranes overnight in
1:1000 dilutions of human phosphor-STAT-6 mouse
monoclonal antibody and human total STAT-6 rabbit pol-
yclonal antibody (Cell Signaling Technology, Beverly,
MA). Secondary antibody incubations were performed for
1 h using 1:10000 dilutions of Alexa Fluor 488 goat anti-
mouse and Alexa Fluor 532 goat anti-rabbit IgG antibod-
ies (Molecular Probes, Carlsbad, CA). Membranes were
washed thrice and scanned using Molecular Imager FX
(a) RT-PCR analysis of IL-4R mRNA expression from NCI-H650 cells Figure 1
(a) RT-PCR analysis of IL-4R mRNA expression from NCI-H650 cells. Total RNA was extracted from confluent cultures and 
analyzed for the presence of IL-4R and GAPDH transcripts by RT-PCR. The amplified products were run on 1% agarose-ethid-
ium bromide gels. Bands at 335 bp (IL-4R) and 1000 bp (GAPDH) were observed. Immunohistochemical determination of IL-
4Rα upon permeabilized NCI-H650 cells using (b) rabbit polyclonal anti-human IL-4Rα antibody (c) and non-immune rabbit 
IgG serum (control). Secondary antibody incubations were performed with Alexa Fluor (568 nm)-labeled mouse antibody. 
Cells were counterstained with DAPI and photographed using dapi: rhodamine filters at 25:2000 ms exposure. Block arrows in 
(1b) are indicative of specific staining to IL-4 receptors on cell surface.
1Kb           GPD           IL-4R          100bp
A
B CRespiratory Research 2006, 7:39 http://respiratory-research.com/content/7/1/39
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system (Bio-Rad, Hercules, CA) at 488 nm and 532 nm.
After Imaging, the blots were stripped and reprobed using
human  β-actin monoclonal mouse primary antibody
(Sigma-Aldrich, Saint Louis, MO) at 1:5000 dilutions.
Signaling pathway analysis
To understand the signaling mechanism associated with
IL-4-mediated MUC4 expression, confluent cultures were
treated with MAPK-selective inhibitor, U0126, a pan-JAK
inhibitor DBI and a JAK3-selective inhibitor, WHI-P131,
at 25, 50 and 100 µM concentrations for 30 min. Follow-
ing inhibitor treatments, the cells were incubated with 2.5
ng/ml of IL-4 for 2 h. Control cultures were treated with
DMSO with or without IL-4. After incubations, total RNA
was isolated reverse transcribed and analyzed by real-time
PCR as described earlier.
Cytotoxicity evaluation
The evaluation of mediator/inhibitor -influenced cytotox-
icity was performed in the above experiments by quantify-
ing the lactate dehydrogenase (LDH) content, using the
Cytotoxicity Detection Kit (Roche Diagnostics Corpora-
tion, Indianapolis, IN).
Statistical analysis
Data obtained from all the experiments was analyzed by
Kruskal-Wallis one-way non-parametric analysis of vari-
ance with post hoc evaluations by Mann-Whitney's rank
sum test (SAS Institute, Cary, NC). A level of significance
was considered at p < 0.05.
Results
IL-4Rα expression in NCI-H650 cells
The expression of IL-4Rα mRNA transcripts was first
established by RT-PCR using conditions previously pub-
lished in the literature [33]. Expected bands at 335 bp for
IL-4R and 1000 bp for glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) were obtained by running amplified
products on 1% agarose-ethidium bromide gels (Fig. 1a).
Localization of IL-4R protein to the cell surface of NCI-
H650 cells was established by immunohistochemistry. IL-
4R staining was observed on NCI-H650 cell surface using
rabbit polyclonal anti-human IL-4Rα antibody but was
absent in cells incubated with non-immune rabbit IgG
(Fig. 1b, 1c).
Induction of MUC4 expression by IL-4
To define the effects of IL-4 on steady state MUC4 mRNA
levels, confluent cultures were treated with 0 to 10 ng/ml
of IL-4 for 2 h. Following treatments, MUC4 levels were
analyzed by real-time PCR. As shown in Fig. 2, IL-4 up-
regulated MUC4 expression in a concentration-dependent
manner, reaching peak expression at 2.5 ng/ml.
Time course of MUC4 gene expression by IL-4 Figure 3
Time course of MUC4 gene expression by IL-4. NCI-H650 
cells were treated with 2.5 ng/ml of IL-4 for indicated times. 
Controls were sham treated. [] MUC4 and [▪] 18S rRNA 
eukaryotic mRNA levels were determined by real-time PCR 
amplification. Data indicated in the graph are mean fold 
increase ± SE over mean control value. The graph summa-
rizes data from three independent experiments with each 
treatment run in triplicate. * significantly different, p < 0.05.
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Dose-dependent expression of MUC4 by IL-4 Figure 2
Dose-dependent expression of MUC4 by IL-4. NCI-H650 
cells were treated with 0 to 10 ng/ml concentrations of IL-4. 
The mRNA levels of MUC4 were determined by real-time 
PCR analysis. Data indicated in the graph are mean fold 
increase ± SE over mean control value. The data are repre-
sentative of three independent experiments with each treat-
ment run in triplicate. * significantly different, p < 0.05.
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In order to determine whether IL-4 modulated expression
of MUC4 is time-dependent, triplicate cultures were incu-
bated with 2.5 ng/ml of IL-4 from 2, 4, 6, 8 and 12 h.
MUC4 mRNA levels steadily increased after 1 h and
reached maximum expression at 8 h (Fig. 3).
Transcriptional regulation of MUC4 by IL-4
To investigate the regulatory mechanism involved in up-
regulation of MUC4, nuclear run-on transcription assays
were performed. The results revealed, higher MUC4 levels
in nuclei extracted from IL-4 treated cells incubated with
a mixture of NTP's (Tr(+NTPs)) over nuclei from treated
cells incubated without NTP's (Tr(-NTPs)). However, no
significant difference (p > 0.05) in transcription levels of
MUC4 were observed between nuclei from control cells
incubated with NTP's (C(+NTPs)) over those incubated
without NTP's (C(-NTPs)) (Fig. 4).
MUC4 protein expression
Western blotting experiments using a 1G8 antibody spe-
cific to ASGP-2 region of human MUC4 mucin were per-
formed to determine the effects of IL-4 upon MUC4
glycoprotein expression. A specific band at 140 kDa was
observed on analyzing the plasma membrane protein
preparation in IL-4 stimulated cells (Fig. 5).
Effects of signaling inhibitors
Pre-treatments with signaling inhibitors at 25 µM concen-
tration revealed that the JAK inhibitors DBI and WHI-
P131 substantially reduced IL-4-stimulated MUC4 expres-
sion (Fig. 6, 7). Increasing the concentration of the
WHIP131 to 50 (data not shown) and 100 µM, further
down-regulated gene expression in a concentration-
dependent manner. No significant change (p = 0.4) in
MUC4 levels was noticed upon increasing DBI concentra-
tion from 25 to 100 µM. Cultures pre-treated with U0126
before IL-4 stimulus showed no change (p > 0.05) in
MUC4 expression over cultures treated with IL-4 alone
(Fig. 8).
STAT-6 activation
The activation of STAT-6 by IL-4 is represented by down-
stream phosphorylation of STAT-6. Therefore, we exam-
ined the phosphorylation of STAT-6 (p-STAT-6) in treated
and control cells by western blotting using an anti-phos-
pho-STAT6 antibody and anti-STAT-6 antibody. After IL-4
stimulation, elevated p-STAT-6 levels were evident within
5–20 min (Fig. 9). No detectable p-STAT-6 levels were
observed in untreated control and IL-4 treated cells at 0
min.
Discussion
Airway-epithelial cell lines such as A549, Calu-3, HM3,
HT29-MTX and H292 have been used as in-vitro model
systems for MUC gene expression studies involving a vari-
ety of inflammatory mediators [25,34-37], air pollutants
[38] and bacterial endotoxins [39,40]. In an earlier study,
a similar cell line, NCI-H650, was demonstrated to secrete
mucins in culture conditions by a variety of secretagogues,
such as 8-bromocyclic AMP, neutrophil elastase and ion-
omycin, using a polyclonal antibody to normal human
tracheobronchial mucin (HTM-1) [29]. Utilizing the same
cell line in the present study, we demonstrated the poten-
tial role of IL-4 on membrane bound mucin MUC4 regu-
lation in human airways.
The biological actions of IL-4 are initiated by binding to
its receptors expressed in varied cell types. Human IL-4R
occurs naturally as a membrane bound form and a smaller
soluble isoform in airways of asthmatics. The soluble IL-
4R lacks the trans-membrane and cytoplasmic domains
consistent with the larger membrane bound receptor. Due
to the absence of cytoplasmic domains, the soluble recep-
tor upon binding to IL-4 does not induce down-stream
signaling cascades [41,42]. In this study, the presence of
IL-4R transcripts in NCI-H650 cells was initially deter-
mined by RT-PCR experiments. Localization of IL-4R to
NCI-H650 cell surface was established by immunohisto-
Transcriptional regulation of MUC4 by IL-4 Figure 4
Transcriptional regulation of MUC4 by IL-4. Nuclei were iso-
lated from IL-4 treated and control cells at two separate time 
points of 4 h and 8 h. The extracted nuclei were incubated 
with or without a mixture of NTP's (0.5 mM each) for 45 
min. Real-time PCR amplifications were performed on total 
RNA extracted from: C(-NTP), untreated nuclei of control 
cells; C(+NTP), NTP treated nuclei of control cells; Tr(-
NTP), untreated nuclei from IL-4-treated cells; and 
Tr(+NTP), NTP treated nuclei from IL-4-treated cells. Data 
indicated in the graph are mean fold increase ± SE over mean 
control value. The graph summarizes data from three inde-
pendent experiments with triplicate samples. * significant 
increase (p < 0.05) ; ! no significant difference (p > 005)
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chemical studies using a rabbit polyclonal antibody spe-
cific to the C-terminal cytoplasmic domain of human
membrane bound IL-4Rα. Earlier, the presence of mem-
brane bound IL-4R was demonstrated in airway epithelial
cells and cell lines [25].
Interestingly, IL-4Rα subunit forms part of the signaling
complex for IL-4 and IL-13 receptors [43]. In addition,
both IL-4 and IL-13 genes have been reported to be
increased 18 h after allergen exposure in patients with
allergic asthma [44]. Intranasal instillation of IL-4 or IL-13
in mice developed airway esonophilia and AHR, with no
such symptoms in transgenic mice lacking IL-4Rα in air-
ways, further emphasizing the role of IL-4Rα in develop-
ment of asthmatic phenotype [45]. While emphasizing
the critical role of IL-13 in asthma, this study explored the
relevance of IL-4 in regulation a membrane bound mucin,
MUC4.
Exposure of NCI-H650 cells to IL-4 increased steady state
MUC4  mRNA in a concentration and time dependent
manner, reaching peak expression levels at 2.5 ng/ml and
8 h. Further increasing, the concentration or times of
exposure reduced MUC4 levels. This phenomenon could
be due to release of Suppression of Cytokine Signaling
(SOCS) factors that regulate IL-4 mediated gene expres-
sion by negative feed back inhibition [46,47]. These
results are largely confirmatory of studies where IL-4 was
shown to up-regulate MUC genes in-vitro [25] and in-vivo
[48]. Our findings stand in contrast to reports where IL-4
MUC4 glycoprotein expression on IL-4 stimulus Figure 5
MUC4 glycoprotein expression on IL-4 stimulus. Panel (A): Confluent cells were treated with (Tr) 2.5 ng/ml of IL-4 for 8 h fol-
lowed by a 16 h chase period in fresh medium without IL-4. (Ct) Untreated control cells. Plasma membrane protein (50 µg) 
was resolved on 4–20% SDS-PAGE gradient gels and evaluated with 1G8 anti-MUC4 monoclonal primary antibody and horse 
radish peroxidase conjugated goat secondary antibody. The Western blots are representative of three separate experiments. 
Panel (B): Commassie blue staining of the gels.
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down-regulated mucin secretion and up-regulated 15-
lipoxygenase enzyme expression (15-LO) in airway epi-
thelial cells [49]. The 15-LO class of dioxygenases
enzymes preferentially metabolize exogenous arachidonic
acid and linoleic acid to 15-hydroxyeicosatetraenoic acid
(15(S)-HETE) and 13-hydroxyoctadecadienoic acid (13-
HODE) [50]. The effects of 15-LO metabolites on mucin
production are unclear and conflicting reports exist on
their ability to regulate mucin production [49,51,52].
Nevertheless, the influence of these mediators in this
study would be minimal as we detected an increase in
MUC4 mRNA levels within 2 h of IL-4 exposure. Our find-
ings reveal a direct effect of IL-4 upon MUC4 gene expres-
sion  in vitro and are based on quantitative PCR
methodology.
In this study, transcriptional up-regulation of MUC4 was
established by nuclear run-on experiments. Our findings
are in accordance with previous studies where, transcrip-
tional enhancement of airway MUC genes 2 and 5AC was
demonstrated in response to cytokines, IL-1β [53] and IL-
9 [54] respectively, in airway epithelial cells. Conversely,
our results differ from reports involving neutrophil
elastase (NE), which increased MUC5AC and MUC4 lev-
els by post-transcriptional mRNA stabilization [37,55].
Interestingly, NE treatment of A549 enhanced MUC1
expression at transcriptional level [56]. These reports indi-
cate the regulatory pattern to be both, gene and mediator
specific.
Western analysis using a 1G8 monoclonal antibody spe-
cific to ASGP-2, a N-glycosylated transmembrane unit of
MUC4β, revealed a 140 kDa band in the plasma protein
fraction isolated from IL-4-treated NCI-H650 cells. The
band obtained was consistent with studies determining
MUC4 expression in human corneal epithelium [57],
endothelial cells [58] and normal human bronchial epi-
thelial (NHBE) cells following NE exposure [55].
The IL-4 – IL-4R interaction can potentate either JAK or
MAPK signaling cascades and consequently, activate
STAT-6. Upon activation, STAT-6 dimerizes, translocates
to the nucleus, and binds to specific promoter regions to
regulate gene transcription [59,60]. With this knowledge,
we investigated the potential effects of a pan-JAK inhibi-
tor, DBI, a JAK3-selective inhibitor, WHI-P131, and a
MAPK inhibitor, U0126, upon IL-4-mediated MUC4
expression. DBI is a potent inhibitor of all members of the
JAK family and has been reported to block JAK/STAT-
dependent proliferation of CTLL cells following IL-4 stim-
ulus [61]. Alternatively, WHI-P131 is a JAK3-selective
inhibitor with no effects on JAK1, JAK2, Syk or Src kinases.
WHI-P131 was identified as an anti-thrombotic agent that
inhibits JAK3 pathway-dependent platelet aggregation
Effects of JAK-3 selective signaling inhibitor (WHI-P131),  upon IL-4-stimulated MUC4 mRNA expression Figure 7
Effects of JAK-3 selective signaling inhibitor (WHI-P131), 
upon IL-4-stimulated MUC4 mRNA expression. NCI-H650 
cells were pretreated with indicated concentrations of WHI-
P131 for 30 min before stimulation with 2.5 ng/ml of IL-4. 
Data indicated in the graph are mean fold increase ± SE over 
mean control value. The graph summarizes data from three 
independent experiments with triplicate samples. * signifi-
cantly different (p < 0.05), ! no statistical significance, (p > 
0.05).
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Effects of pan-JAK signaling inhibitor (DBI), upon IL-4-stimu- lated MUC4 mRNA expression Figure 6
Effects of pan-JAK signaling inhibitor (DBI), upon IL-4-stimu-
lated MUC4 mRNA expression. NCI-H650 cells were pre-
treated with indicated concentrations of DBI for 30 min 
before stimulation with 2.5 ng/ml of IL-4. Data indicated in 
the graph are mean fold increase ± SE over mean control 
value. The graph summarizes data from three independent 
experiments with triplicate samples. * significantly different (p 
< 0.05), ! no statistical significance, (p > 0.05).
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[
62]. U0126 is a selective inhibitor of MEK1 and MEK2
with little effect on other kinases such as ERK, PKC, JNK
and MEKK. U0126 acts as an immunosuppressant by
modulating MAPK dependent IL-2 mRNA levels and
blocking T-cell proliferation following antigenic stimulus
[63].
In this study, DBI pre-treatments markedly decreased
MUC4  expression in IL-4 treated cells, however, no
change in expression levels were detected between pre-
treatments at 25 and 100 µM concentrations. Replication
of the experiments with WHI-P131 at 25, 50 (data not
shown) and 100 µM concentrations down-regulated IL-4
mediated MUC4 mRNA in a dose dependent fashion. No
change in expression levels were detected upon U0126
pre-treatment at varying concentrations with respect to
cells treated with IL-4 alone. While, acknowledging the
possibility of parallel activation of JAK1 and JAK3 path-
ways by IL-4, this study explored the significance of JAK3
signaling cascade on MUC4 gene expression. Our results
are supportive of earlier reports where JAK3 preferential
tyrosine phosphorylation has been reported in response
to cytokines that share the common IL-2 receptor γ-chain
such as IL-4, IL-7, and IL-9 [64-66]. On the other hand,
our results contradict reports where IL-4 treatment has
been shown to elevate MUC2 levels by a MAPK pathway
in human colon cancer cells [67]. These contradictions
Activation of STAT-6 by IL-4 in NCI-H650 cells Figure 9
Activation of STAT-6 by IL-4 in NCI-H650 cells. Western analysis of cell lysates from 2.5 ng/ml IL-4 stimulated cells at indi-
cated time points. STAT-6 activation was detected using an anti-phospho-STAT-6 antibody. The Western blots are represent-
ative of three separate experiments with triplicate samples.
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Effects of MAPK signaling inhibitor (U0126), upon IL-4-stimu- lated MUC4 mRNA expression Figure 8
Effects of MAPK signaling inhibitor (U0126), upon IL-4-stimu-
lated MUC4 mRNA expression. NCI-H650 cells were pre-
treated with indicated concentrations of U0126 for 30 min 
before stimulation with 2.5 ng/ml of IL-4. Data indicated in 
the graph are mean fold increase ± SE over mean control 
value. The graph summarizes data from three independent 
experiments with triplicate samples. ! no statistical signifi-
cance, (p > 0.05).
U0126 (µM)            0                                  100     0                                   25                                 100
IL-4 (2.5ng/ml)        - - +                            +                                    +
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could, in part be explained by reports, which demon-
strated IL-4- dependent MAPK signaling to vary with cell
types [60].
Activation of STAT-6 was detected in IL-4 stimulated NCI-
H650 cells by western blotting using an antiphospho-
STAT-6 antibody. The p-STAT-6 band was evident on
resolving lysates from cells incubated with 2.5 ng/ml of
IL-4 for 2.5 to 15 min. These findings implicate JAK-medi-
ated STAT-6 activation during IL-4-dependent MUC4
enhancement. Our findings are in accordance with studies
where another Th2 cytokine IL-9, was reported to activate
MUC5AC via the JAK/STAT pathway [54].
The molecular mechanisms of MUC4 expression have just
begun to be elucidated. Recent reports have shown that
interferon-γ (IFN-γ) stimulus up-regulates MUC4 through
enhanced STAT-1 expression in human pancreatic tumor
cell line CD18/HPAF. In a similar study, retinoic acid (RA)
treatment of the same cells enhanced MUC4 expression
through TGF-β2-mediated STAT-1 activation [68]. Simul-
taneous treatments with RA and IFN-γ showed synergistic
induction of MUC4 mRNA. Yet, treatment with RA in this
study revealed an inhibition of IFN-γ influenced STAT-1
increase; and exposure to IFN-γ subdued RA influenced
TGF-β2 induction. Consequently, the possibility of
enhanced MUC4 expression through alternate signaling
routes during synergistic interaction, distinct from those
adopted by their constitutive individual mediators has
been hypothesized [69]. In CAPAN-1 and CAPAN-2 cell
lines, MUC4 promoter activation was influenced by epi-
dermal growth factor (EGF) or transforming growth factor
(TGF)-α through a protein kinase C (PKC) cascade [68].
In human esophageal cell line OE33, bile salts transcrip-
tionally regulated MUC4  expression via phosphatidyli-
nositol 3-kinase pathway (PI3K) [70].
To date, overall utility of MUC4 to human lung function
is unclear; yet, its early expression in human fetal develop-
ment [71-74] and its specific and timely expression in
end-differentiated cell types in adults indicate its potential
role in cytodifferentiation [75,76]. Recent studies have
identified Muc4 (rat homologue of human MUC4) as a
ligand for ErbB2 receptor. The binding of Muc4 to ErbB2
receptor alone or to neuregulin activated ErbB3-ErbB2
heterodimeric complex regulates the expression of
p27kip1, a cyclin dependent kinase inhibitor. The forma-
tion of Muc4-ErbB2 complex up-regulates p27kip1 and
promotes cell differentiation, in contrast, Muc4-ErbB2-
ErbB3-neuregulin complex formation represses p27kip1
and activates Akt pathways leading to cell proliferation
[77]. Further, the ability of SMC/Muc4 to alter ErbB2
localization in polarized human colon carcinoma CACO-
2 cells has been demonstrated, indicating a strong physi-
cal association between the two molecules [78]. In an ele-
gant study, ErbB2 activation was ascertained for epithelial
cell repair following NE exposure [79]. In a similar study,
NE treatment significantly enhanced MUC4 (the ligand
for ErbB2) in bronchial epithelia cells in-vitro [55]. NE is
one among a variety of immune cell derived mediators,
which modulate airway inflammation and epithelial tis-
sue destruction in chronic respiratory ailments such as CF
and asthma.
Numerous studies have hinted at elevated IL-4 expression
in bronchoalveolar lavage [80], breath condensate [81]
and serum [82] of asthmatics. Further, evaluation of air-
way biopsies from asthmatic patients has hinted at low,
yet increased MUC4 protein levels over normal healthy
controls [83]. While acknowledging the important roles
of other Th2 cytokines such as IL-5 and IL-13 in regulating
MUC genes in asthmatic airways, this study explored the
relevance of IL-4 upon a membrane bound mucin MUC4
via the common IL-4Rα chain. Our studies revealed that
IL-4 induces MUC4 gene and protein levels. The enhance-
ment was determined primarily to be at the transcrip-
tional stage. In addition, inhibitor studies revealed that IL-
4 modulates MUC4 expression by JAK3 selective-STAT-6
pathway.
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